Published in Semin Immunopathol on July 26, 2012
Occult hepatitis B virus infection in anti-HBs-positive infants born to HBsAg-positive mothers in China. PLoS One (2013) 0.98
Occult hepatitis B virus infection. World J Hepatol (2014) 0.90
Potential mutations associated with occult hepatitis B virus status. Hepat Mon (2014) 0.87
Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variants. J Clin Virol (2014) 0.85
Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat (2013) 0.84
Occult hepatitis B virus and hepatocellular carcinoma. World J Gastroenterol (2014) 0.84
The clinical significance of occult HBV infection. Ann Gastroenterol (2014) 0.83
Occult hepatitis B virus infection and blood transfusion. World J Hepatol (2015) 0.81
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. PLoS One (2013) 0.81
Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol (2015) 0.79
Absence of occult hepatitis B virus infection in sera of diabetic children and adolescents following hepatitis B vaccination. Hum Vaccin Immunother (2014) 0.78
Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer (2013) 0.78
Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis (2015) 0.77
Diagnosis of hepatitis B. Ann Transl Med (2016) 0.77
Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2013) 0.77
Persistence of Hepatitis C Virus Traces after Spontaneous Resolution of Hepatitis C. PLoS One (2015) 0.76
Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance. PLoS One (2014) 0.76
The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China. PLoS One (2014) 0.76
Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. PLoS One (2014) 0.76
Occult HBV Infection May Be Transmitted through Close Contact and Manifest as an Overt Infection. PLoS One (2015) 0.76
Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance. World J Hepatol (2015) 0.76
No evidence for occult HBV infection in hepatitis B vaccine non-responders. Iran J Microbiol (2014) 0.76
Occult hepatitis B virus infection among Mexican human immunodeficiency virus-1-infected patients. World J Gastroenterol (2014) 0.76
The Envelope Gene of Hepatitis B Virus Is Implicated in Both Differential Virion Secretion and Genome Replication Capacities between Genotype B and Genotype C Isolates. Viruses (2017) 0.75
Hepatitis B virus upregulates host expression of α-1,2-mannosidases via the PPARα pathway. World J Gastroenterol (2016) 0.75
HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses (2017) 0.75
Genetic variation of occult hepatitis B virus infection. World J Gastroenterol (2016) 0.75
Update on occult hepatitis B virus infection. World J Gastroenterol (2016) 0.75
Occult HBV Infection in Immunized Neonates Born to HBsAg-Positive Mothers: A Prospective and Follow-Up Study. PLoS One (2016) 0.75
Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center. Braz J Med Biol Res (2014) 0.75
Plasma Epstein-Barr virus and Hepatitis B virus in non-Hodgkin lymphomas: Two lymphotropic, potentially oncogenic, latently occurring DNA viruses. Indian J Med Paediatr Oncol (2016) 0.75
Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis (2015) 0.75
Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol (2016) 0.75
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection. Neurol Sci (2016) 0.75
Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia. PLoS One (2017) 0.75
Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing. Transfus Med Hemother (2017) 0.75
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol (2001) 5.81
Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci U S A (1989) 3.67
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med (1996) 3.60
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol (2008) 3.44
"Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet (1994) 3.33
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med (1981) 3.17
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med (1999) 3.08
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
Occult hepatitis B virus infection. J Hepatol (2006) 2.79
Control of cccDNA function in hepatitis B virus infection. J Hepatol (2009) 2.41
State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci U S A (1981) 2.37
Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med (1978) 2.30
Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology (2004) 2.11
Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology (1975) 2.08
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol (2009) 2.00
Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest (1996) 1.96
Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet (1988) 1.95
Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology (2012) 1.92
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest (2012) 1.81
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 1.81
Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int (2008) 1.76
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology (2011) 1.74
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A (2009) 1.74
Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis (2007) 1.73
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol (2009) 1.72
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Transfusion-transmitted hepatitis B virus infection. J Hepatol (2009) 1.70
Occult hepatitis B virus infection: a covert operation. J Viral Hepat (2009) 1.69
Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med (2011) 1.69
Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol (2007) 1.65
Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta (2010) 1.65
Occult hepatitis B virus infection in a North American community-based population. J Hepatol (2005) 1.64
Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl (2010) 1.59
New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol (2005) 1.57
Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol (2009) 1.46
Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol (2000) 1.44
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology (2008) 1.42
Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int (2011) 1.39
Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol (2008) 1.31
Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology (2007) 1.31
Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion (2008) 1.31
Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail (2006) 1.29
Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res (2006) 1.28
High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica (2006) 1.28
Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology (2003) 1.24
Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology (2009) 1.24
Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology (2010) 1.23
Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol (2010) 1.23
High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology (2004) 1.23
Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation (2005) 1.22
Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology (1998) 1.22
Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther (2005) 1.21
Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol (2009) 1.19
Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol (2006) 1.16
Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology (2010) 1.14
Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect (2006) 1.10
Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol (2007) 1.10
Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol (2009) 1.10
Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol (2007) 1.09
The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood (2005) 1.08
Chromatin organization and virus gene expression. J Cell Physiol (2008) 1.08
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica (2009) 1.08
Methylation regulates hepatitis B viral protein expression. J Infect Dis (2009) 1.07
Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol (2005) 1.06
Fatal reactivation of hepatitis B with temozolomide. N Engl J Med (2007) 1.06
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis (2008) 1.04
Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis (2011) 1.03
Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion (2007) 1.02
Occult HBV infection in continuous ambulatory peritoneal dialysis and hemodialysis patients. Ren Fail (2010) 1.01
What is the clinical impact of occult hepatitis B virus infection? Lancet (2005) 1.01
Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta (2009) 1.01
Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology (2011) 1.00
Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. Sci Signal (2012) 1.00
Challenges in hepatitis B detection among blood donors. Curr Opin Hematol (2011) 1.00
Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology (2009) 0.99
DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. J Infect Dis (2010) 0.96
Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst (2009) 0.95
Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest (1994) 0.94
Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma (2009) 0.94
Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol (2011) 0.93
Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan. J Med Virol (2004) 0.93
Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant (2010) 0.93
Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat (2010) 0.92
Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl (2011) 0.92
T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol (2011) 0.91
Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice. J Exp Med (2000) 0.88
Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease? Ann Hepatol (2005) 0.86
Disease progression and liver cancer in the ferroportin disease. Gut (2007) 0.85
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol (2009) 0.85
Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine (2009) 0.85
Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clin Transplant (2009) 0.79
What is the clinical significance of the high prevalence of occult hepatitis B in US liver transplant patients with chronic hepatitis C? Liver Transpl (2008) 0.78
Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS (2007) 0.77
[Morgagni-Réaumur correspondence in the Public Library of Forli]. Gesnerus (1972) 0.76
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Occult hepatitis B virus infection. J Hepatol (2006) 2.79
Control of cccDNA function in hepatitis B virus infection. J Hepatol (2009) 2.41
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest (2012) 1.81
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A (2009) 1.74
Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol (2013) 1.50
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology (2008) 1.42
Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer (2006) 1.33
Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol (2008) 1.31
The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene (2002) 1.13
Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol (2002) 1.10
Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol (2011) 1.08
What is the clinical impact of occult hepatitis B virus infection? Lancet (2005) 1.01
Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. J Hepatol (2004) 0.94
Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol (2010) 0.90
Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses. Oncogene (2002) 0.88
Hepatitis B vaccination. Hum Vaccin Immunother (2014) 0.88
Disease progression and liver cancer in the ferroportin disease. Gut (2007) 0.85
High prevalence of non-organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy. Dig Dis Sci (2003) 0.85
Celiac disease and non-organ-specific autoantibodies in patients with chronic hepatitis C virus infection. Dig Dis Sci (2008) 0.84
Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study. Liver Int (2005) 0.83
Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis (2012) 0.83
Therapy of occult hepatitis B virus infection and prevention of reactivation. Intervirology (2014) 0.82
Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol (2002) 0.81
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis (2011) 0.81
NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C. Antivir Ther (2013) 0.79
Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS (2007) 0.77
Clinical virology of hepatitis B virus infection. J Hepatol (2003) 0.77
Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy. Dig Liver Dis (2011) 0.76
Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C. Hepatology (2011) 0.76
Lack of the NS5B S282T mutation in HCV isolates from liver tissue of treatment-naive patients with HCV genotype-1b infection. Antivir Ther (2014) 0.75
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. Dig Liver Dis (2013) 0.75
Case Report: Atrial Fibrillation After Intravenous Administration of Iodinated Contrast Medium in a Patient With Hepatocellular Carcinoma. Medicine (Baltimore) (2015) 0.75
Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography. Medicine (Baltimore) (2016) 0.75
PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore) (2017) 0.75